Posted by Michael Wonder on 29 Aug 2023
Australia knocks back application for diabetes drug that could overshadow Ozempic
29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants the much-hyped weight loss medication to be available on local shelves by the end of the year.
The Pharmaceutical Benefits Advisory Committee in a July ruling said it did not recommend Eli Lilly’s application for tirzepatide, which is Mounjaro’s active ingredient, to be added to Australia’s Pharmaceutical Benefits Scheme.
